These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 21209946)

  • 1. Formation and toxicity of soluble polyglutamine oligomers in living cells.
    Lajoie P; Snapp EL
    PLoS One; 2010 Dec; 5(12):e15245. PubMed ID: 21209946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detecting soluble polyQ oligomers and investigating their impact on living cells using split-GFP.
    Lajoie P; Snapp EL
    Methods Mol Biol; 2013; 1017():229-39. PubMed ID: 23719920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploding the Repeat Length Paradigm while Exploring Amyloid Toxicity in Huntington's Disease.
    Wetzel R
    Acc Chem Res; 2020 Oct; 53(10):2347-2357. PubMed ID: 32975927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic.
    Takahashi T; Kikuchi S; Katada S; Nagai Y; Nishizawa M; Onodera O
    Hum Mol Genet; 2008 Feb; 17(3):345-56. PubMed ID: 17947294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fragments of HdhQ150 mutant huntingtin form a soluble oligomer pool that declines with aggregate deposition upon aging.
    Marcellin D; Abramowski D; Young D; Richter J; Weiss A; Marcel A; Maassen J; Kauffmann M; Bibel M; Shimshek DR; Faull RL; Bates GP; Kuhn RR; Van der Putten PH; Schmid P; Lotz GP
    PLoS One; 2012; 7(9):e44457. PubMed ID: 22984513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ubiquitin conjugating enzyme Ube2W regulates solubility of the Huntington's disease protein, huntingtin.
    Wang B; Zeng L; Merillat SA; Fischer S; Ochaba J; Thompson LM; Barmada SJ; Scaglione KM; Paulson HL
    Neurobiol Dis; 2018 Jan; 109(Pt A):127-136. PubMed ID: 28986324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel human embryonic stem cell-derived Huntington's disease neuronal model exhibits mutant huntingtin (mHTT) aggregates and soluble mHTT-dependent neurodegeneration.
    Lu B; Palacino J
    FASEB J; 2013 May; 27(5):1820-9. PubMed ID: 23325320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational analysis implicates the amyloid fibril as the toxic entity in Huntington's disease.
    Drombosky KW; Rode S; Kodali R; Jacob TC; Palladino MJ; Wetzel R
    Neurobiol Dis; 2018 Dec; 120():126-138. PubMed ID: 30171891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heat shock promotes inclusion body formation of mutant huntingtin (mHtt) and alleviates mHtt-induced transcription factor dysfunction.
    Chen JY; Parekh M; Seliman H; Bakshinskaya D; Dai W; Kwan K; Chen KY; Liu AYC
    J Biol Chem; 2018 Oct; 293(40):15581-15593. PubMed ID: 30143534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington's disease molecular pathogenesis.
    Miller J; Arrasate M; Shaby BA; Mitra S; Masliah E; Finkbeiner S
    J Neurosci; 2010 Aug; 30(31):10541-50. PubMed ID: 20685997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Huntingtin affinity for partners is not changed by polyglutamine length: aggregation itself triggers aberrant interactions.
    Davranche A; Aviolat H; Zeder-Lutz G; Busso D; Altschuh D; Trottier Y; Klein FA
    Hum Mol Genet; 2011 Jul; 20(14):2795-806. PubMed ID: 21518730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic recruitment of active proteasomes into polyglutamine initiated inclusion bodies.
    Schipper-Krom S; Juenemann K; Jansen AH; Wiemhoefer A; van den Nieuwendijk R; Smith DL; Hink MA; Bates GP; Overkleeft H; Ovaa H; Reits E
    FEBS Lett; 2014 Jan; 588(1):151-9. PubMed ID: 24291262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo.
    Legleiter J; Mitchell E; Lotz GP; Sapp E; Ng C; DiFiglia M; Thompson LM; Muchowski PJ
    J Biol Chem; 2010 May; 285(19):14777-90. PubMed ID: 20220138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solid-State Nuclear Magnetic Resonance on the Static and Dynamic Domains of Huntingtin Exon-1 Fibrils.
    Isas JM; Langen R; Siemer AB
    Biochemistry; 2015 Jun; 54(25):3942-9. PubMed ID: 26020223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.
    Luis-Ravelo D; Estévez-Silva H; Barroso-Chinea P; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Acevedo-Arozena A; Marcellino D; González-Hernández T
    Exp Neurol; 2018 Jan; 299(Pt A):137-147. PubMed ID: 29056363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tracking mutant huntingtin aggregation kinetics in cells reveals three major populations that include an invariant oligomer pool.
    Olshina MA; Angley LM; Ramdzan YM; Tang J; Bailey MF; Hill AF; Hatters DM
    J Biol Chem; 2010 Jul; 285(28):21807-16. PubMed ID: 20444706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel potentially toxic oligomers formed in vitro from mammalian-derived expanded huntingtin exon-1 protein.
    Nucifora LG; Burke KA; Feng X; Arbez N; Zhu S; Miller J; Yang G; Ratovitski T; Delannoy M; Muchowski PJ; Finkbeiner S; Legleiter J; Ross CA; Poirier MA
    J Biol Chem; 2012 May; 287(19):16017-28. PubMed ID: 22433867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of flanking sequences and cellular context on subcellular behavior and pathology of mutant HTT.
    Chongtham A; Bornemann DJ; Barbaro BA; Lukacsovich T; Agrawal N; Syed A; Worthge S; Purcell J; Burke J; Chin TM; Marsh JL
    Hum Mol Genet; 2020 Mar; 29(4):674-688. PubMed ID: 31943010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioinformatics analysis of Ras homologue enriched in the striatum, a potential target for Huntington's disease therapy.
    Carbo M; Brandi V; Pascarella G; Staid DS; Colotti G; Polticelli F; Ilari A; Morea V
    Int J Mol Med; 2019 Dec; 44(6):2223-2233. PubMed ID: 31638189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of overexpression of huntingtin proteins on mitochondrial integrity.
    Wang H; Lim PJ; Karbowski M; Monteiro MJ
    Hum Mol Genet; 2009 Feb; 18(4):737-52. PubMed ID: 19039036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.